Key Points {#FPar1}
==========

Plasma polyethylene glycol (PEG) concentrations were analysed in rats and humans treated repeatedly with the PEGylated factor VIII product N8-GP (turoctocog alfa pegol; Esperoct^®^) for periods of up to 1 year (rats) and 5 years (humans).Measured PEG concentrations in plasma were shown to align with values predicted using a semi-mechanistic plasma-tissue pharmacokinetic model based on a single-dose pharmacokinetics and distribution study conducted in rats.PEG levels reached steady state in plasma from rats and humans treated with N8-GP, and there was no unexpected increase above steady-state levels.

Introduction {#Sec1}
============

Haemophilia A is a serious and potentially life-threatening bleeding disorder caused by a genetic deficiency in clotting factor VIII (FVIII). The classical way of treating haemophilia A has been replacement therapy with the missing clotting factor, either as on-demand treatment when bleeding occurs or as prophylactic treatment to prevent bleeding episodes. Because unmodified FVIII products have a relatively short half-life of 8--12 h \[[@CR1]\], several FVIII products with prolonged systemic circulation have been developed to maintain higher FVIII activity levels with fewer injections.

One of the most widely used techniques to extend the circulation half-life of a protein/peptide is via conjugation with polyethylene glycol (PEG). PEGylation results in half-life prolongation because of (1) decreased renal excretion resulting from an increase in the hydrodynamic volume of the molecule and (2) slower enzymatic degradation of the active moiety because the protein backbone is shielded \[[@CR2]\]. The principle of PEGylation has been applied to N8-GP \[turoctocog alfa pegol; Esperoct^®^ (Novo Nordisk A/S, Denmark)\], an extended half-life FVIII molecule that has been approved for the treatment of haemophilia A in the EU, USA, Canada, Switzerland, and Japan. N8-GP is derived from the site-directed conjugation of a single-branched, 40-kDa PEG molecule to a unique *O*-linked glycan in the B domain of the recombinant FVIII (rFVIII) protein N8 \[turoctocog alfa; NovoEight^®^ (Novo Nordisk A/S)\] \[[@CR3]\]. It has a safety profile similar to that of unmodified FVIII products and improved pharmacokinetics \[[@CR4]--[@CR6]\].

In general, PEGylated protein/peptide conjugates can be considered to comprise two distinct and structurally different moieties: (1) the active moiety (the protein/peptide) and (2) the PEG moiety. When the PEGylated protein is taken up by tissues, the active component is degraded by proteases, and fragments are excreted (Fig. [1](#Fig1){ref-type="fig"}). The enzymatically and chemically stable PEG moiety is then released intact back into the circulation and subsequently excreted, predominantly in urine \[[@CR7]\]. The respective protein/peptide and the PEG moiety are therefore eliminated from tissues and plasma at different rates. This difference in biological fate and thereby also in kinetics has resulted in concerns regarding long-term exposure to PEGylated drugs and the hypothetical potential for the accumulation of PEG in certain tissues (e.g. the choroid plexus, kidney and liver), possibly adversely impacting their function \[[@CR8], [@CR9]\]. However, these concerns are only valid if the PEG moiety is not eliminated from tissues or plasma or if the dose and exposure level is adversely high \[[@CR10]\].Fig. 1Turoctocog alfa pegol (N8-GP) comprises two distinct moieties with differing pharmacokinetic characteristics. The 40-kDa PEG moiety is attached to an *O*-linked glycan in the 21-amino acid truncated B domain of rFVIII (turoctocog alfa). Upon activation, the B domain harbouring the PEG moiety is cleaved from the rFVIII molecule, leaving two separate molecules with different half-lives (i.e. the free PEG and the activated rFVIII molecule) \[[@CR3]\]. *PEG* polyethylene glycol, *rFVIII* recombinant factor VIII

Elimination of PEG from tissues and plasma has been demonstrated in various animal species with a number of PEGylated proteins \[[@CR11]--[@CR13]\]. For N8-GP, the tissue distribution of PEG was previously investigated in rats receiving a single bolus dose of either N8-GP containing a \[^3^H\]-labelled PEG moiety or 40-kDa \[^3^H\]PEG alone \[[@CR14]\]. N8-GP and PEG were shown to be widely distributed without selective distribution to any organ or tissue. As expected, radiolabelled PEG molecules were eliminated from all organs and excreted intact in both urine and faeces. The majority of radioactivity was excreted within 1--2 weeks after dosing.

PEG levels in plasma and tissues are governed by the PEG dose, dose frequency and duration of treatment. Since the elimination rate of PEG is slower than that of FVIII, it is to be expected, based on basic pharmacokinetic principles that repeated dosing leads to an initial increase in PEG levels until a plateau concentration (steady-state level) is reached. Steady-state levels are then maintained when input (dose amount and frequency) and output (elimination) rates are in equilibrium (Fig. [2](#Fig2){ref-type="fig"}). Again, according to pharmacokinetic theory, the general rule is that the time to reach steady state is determined by the elimination half-life. Though steady state is often said to be achieved after approximately five times the half-life of the molecule \[[@CR15]\], in clinical practice, steady state can be considered to have been reached after 3.3 times the half-life where \~ 90% of steady-state levels have been achieved \[[@CR16]\].Fig. 2Steady-state PEG levels are expected in patients receiving chronic treatment with PEGylated molecules. Steady state is achieved when there is equilibrium between the rate of input into plasma (dose and dosing frequency) and the rate of output (elimination from the tissue) \[[@CR7], [@CR8]\]. PEG is excreted predominantly via urine but also in faeces in small amounts \[[@CR14]\]. *PEG* polyethylene glycol

The consequences of different steady-state PEG levels can be assessed in repeat-dose toxicology studies. For N8-GP, a 52-week repeat-dose toxicology study in Rowett nude rats was conducted with intravenous administration at a dose range of 50--1200 IU/kg every 4th day (Q4D) \[[@CR17]\]. No treatment-related adverse reactions or treatment-related changes in any organ were reported in this study, even at doses far beyond the clinical dose (maximum dose cohort: 1200 IU/kg Q4D). PEG was also not detected in brain or choroid plexus tissue over the duration of the 52-week study in rats treated with the maximum dose.

Even though no adverse findings were reported in the rat toxicology study, analysis of PEG plasma exposure is valuable to demonstrate that expected steady-state levels are reached. Plasma PEG levels can also serve as a surrogate marker to show the extent of tissue exposure in animal and human studies. However, analysis of PEG plasma concentrations was not originally planned in the N8-GP rat toxicology study as assays available at the time of conduct did not have the level of sensitivity required. Instead, steady-state plasma and tissue concentrations were predicted using a semi-mechanistic plasma-tissue pharmacokinetic model based on a single-dose pharmacokinetic and distribution study conducted in rats \[[@CR14]\].

Recently, a contract research organisation was identified that could analyse low plasma PEG concentrations using a sensitive liquid chromatography--tandem mass spectrometry (LC--MS/MS) method. Therefore, leftover plasma samples from the chronic rat toxicity study could be used to retrospectively analyse plasma PEG levels. In addition, human plasma samples from the pathfinder clinical trial programme, which aimed to examine the pharmacokinetics, safety and efficacy of N8-GP in adult/adolescent patients aged ≥ 12 years (pathfinder2; NCT01480180) and children aged \< 12 years (pathfinder5; NCT01731600), were also available for analysis. Although PEG plasma exposure was not initially part of the clinical protocol, it could also be measured retrospectively, with consent, in duplicate samples collected for analysis of antidrug antibodies.

Here, we describe measured PEG plasma concentrations in rats and humans following repeated dosing with N8-GP. Measured PEG levels in rats and humans were compared with steady-state levels predicted using a semi-mechanistic plasma-tissue pharmacokinetic model developed based on single-dose rat distribution data.

Material and Methods {#Sec2}
====================

Laboratory Animals {#Sec3}
------------------

Unused plasma samples from an antidrug antibody analysis performed during a chronic 52-week toxicity study in Rowett nude rats were selected \[[@CR17]\]. A total of 159 plasma samples were analysed from individual male rats receiving 0, 50, 150, 500, or 1200 IU/kg of N8-GP Q4D. PEG levels were also analysed 2 weeks after treatment cessation in the highest dose group. To calculate mean PEG exposure, samples that were below the lower limit of quantification (LLoQ) were set to half of the LLoQ defined in Sect. [2.3](#Sec5){ref-type="sec"}.

Patients and Sample Collection {#Sec4}
------------------------------

A total of 184 human plasma samples from 62 paediatric patients and 121 adolescent/adult patients treated with N8-GP were analysed by LC--MS/MS (two samples were obtained from one paediatric patient). Paediatric samples were taken from patients after \~ 3--4.5 years of 60 IU/kg twice-weekly dosing with N8-GP as part of the pathfinder5 trial \[[@CR5]\]. Adult/adolescent samples were taken after \~ 2--5 years of 50 IU/kg Q4D dosing with N8-GP as part of pathfinder2 \[[@CR4], [@CR18]\]. To calculate mean PEG exposure, samples that were below the LLoQ were set to half of the LLoQ defined in Sect. [2.3](#Sec5){ref-type="sec"}.

Liquid Chromatography-Tandem Mass Spectrometry Method for PEG Analysis {#Sec5}
----------------------------------------------------------------------

Quantification of total PEG (sum of free and conjugated) was performed in rat and human plasma samples by LC--MS/MS. Briefly, rat and human plasma samples were prepared for analysis by adding an internal standard (D-PEG-60k) and pronase protease. After mixing on a thermomixer, MeOH was added prior to LC--MS/MS analysis. Samples were measured with an API6500 Q-trap mass spectrometer (Ab Sciex, Canada), and data were analysed using Analyst^®^ 1.6.2 software (Ab Sciex, Canada). The LLoQ was 13.7 ng/mL in rat plasma and 10 ng/mL in human plasma. Data acquisition and analysis were performed by pharm-analyt Labor GmbH, Baden, Austria.

Model Prediction {#Sec6}
----------------

The pharmacokinetic model that was used to predict PEG exposure in the chronic rat toxicity study and human trials was a semi-mechanistic, multi-compartment, plasma-tissue model created in Phoenix^®^ WinNonlin^®^ version 6.4 (Certara USA, Inc., Princeton, NJ, USA) using the non-linear mixed-effect module. The model was based on a single-dose rat N8-GP distribution study using a radiolabelled PEG moiety \[[@CR14]\] that simultaneously described the plasma and tissue radioactivity data with plasma concentrations driving tissue levels. Standard allometric scaling of the relevant model parameters was performed in order to predict plasma and tissue PEG levels in humans.

Results {#Sec7}
=======

Plasma PEG Levels Did Not Increase Over Time in Samples Obtained from Rats Receiving N8-GP as Part of a 52-Week Toxicity Study {#Sec8}
------------------------------------------------------------------------------------------------------------------------------

While all plasma samples from the 0 and 50 IU/kg Q4D dose groups were below the LLoQ (\< 13.7 ng/mL), plasma PEG concentrations increased in a dose-dependent manner over the 150--1200 IU/kg dose range (Fig. [3](#Fig3){ref-type="fig"}). For the dose levels with detectable PEG levels (150--1200 IU/kg), mean plasma PEG concentrations remained stable over the study period and did not increase between 26 and 52 weeks (Fig. [3](#Fig3){ref-type="fig"}). Mean plasma PEG levels decreased from 85.1 to 33.0 ng/mL after 2 weeks' recovery in the highest dose group. Measured plasma PEG levels were in line with the model-predicted steady-state levels. In addition, the model also represented the observed decline in the mean plasma PEG concentration seen after treatment cessation. Steady-state plasma PEG levels were predicted to have been reached within 1.5 months of the 52-week (12-month) dosing period (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Predicted and measured PEG concentrations in plasma from rats after 26 and 52 weeks' exposure to N8-GP and 2 weeks after treatment cessation. Predicted (solid lines) and measured (squares ± standard deviation) PEG concentrations are shown. To calculate mean PEG exposure, values \< LLoQ were set to 6.85 ng/mL, which was half of the LLoQ. In the high-dose group (1200 IU/kg), mean PEG values were 92.8 ng/mL (26 weeks), 85.1 ng/mL (52 weeks) and 33.0 ng/mL (54 weeks). *LLoQ* lower limit of quantification, *N8-GP* turoctocog alfa pegol, *PEG* polyethylene glycol, *Q4D* every 4th day

Plasma PEG Levels Reached Steady State in Children, Adolescents and Adults Receiving Long-Term Treatment with N8-GP {#Sec9}
-------------------------------------------------------------------------------------------------------------------

Measured mean PEG plasma concentrations for children, adolescents and adults receiving treatment with N8-GP for periods of up to 5 years are reported in Table [1](#Tab1){ref-type="table"}. Of a total of 184 human samples analysed, 51 adult and adolescent patient samples were below the LLoQ (10 ng/mL). Detectable PEG concentrations ranged from 10.0 to 35.9 ng/mL in plasma from paediatric patients and from 10.1 to 34.2 ng/mL in adults and adolescents. Interpatient variation in plasma PEG levels was relatively low.Table 1Measured PEG levels in children, adolescent and adults after 3--5 years of exposure to N8-GPTreatment groupDose (IU/kg)Dose interval*n*Mean plasma PEG levels (ng/mL ± SD)Children60Twice weekly6318.5 ± 6.9Adults and adolescents^a^50Q4D12110.7 ± 5.5*LLoQ* lower limit of quantification, *N8-GP* turoctocog alfa pegol, *PEG* polyethylene glycol, *Q4D* every 4th day, *SD* standard deviation^a^Of a total of 121 samples analysed, 51 samples were below the LLoQ. To calculate mean PEG levels, these samples were set to half the LLoQ (5 ng/mL)

Figure [4](#Fig4){ref-type="fig"} shows the measured plasma PEG concentrations from individual children, adolescents and adults along with the model-predicted steady-state PEG level. Although the dose in children was slightly higher than in adults (60 IU/kg twice weekly vs. 50 IU/kg Q4D), model-predicted steady-state PEG concentrations were similar in children and adults. This is likely due to the faster clearance rate in children. Steady-state plasma PEG concentrations in patients were predicted to be reached within 6 months. The actual measured plasma PEG concentrations in humans were slightly lower than predicted.Fig. 4Predicted and measured PEG concentrations in children, adolescents and adults measured after 2--5 years of exposure to N8-GP. Children (pathfinder5) were treated with 60 IU/kg N8-GP twice weekly (open triangles) \[[@CR5]\]. Adolescents and adults (pathfinder2) were treated with 50 IU/kg N8-GP Q4D (open squares) \[[@CR4], [@CR6]\]. Mean PEG exposure during the 52-week rat toxicity study \[[@CR17]\] is indicated by the upper dotted line, and the LLoQ is shown by the lower dotted line. Predicted mean PEG exposure in children, adolescents and adults (grey solid line) is shown as a reference. The mean measured plasma PEG concentration for children, adolescents and adults was 13.3 ng/mL. *LLoQ* lower limit of quantification, *N8-GP* turoctocog alfa pegol, *PEG* polyethylene glycol, *Q4D* every 4th day

Discussion {#Sec10}
==========

Development of the PEGylated N8-GP molecule has enabled extension of the mean terminal half-life to 19 h, which was observed to be 1.6-fold higher than the patients' previous standard FVIII products \[[@CR6]\]. Once separated, the two distinct parts of N8-GP, that is the rFVIII and the attached PEG molecule, exhibited different pharmacokinetic characteristics and make use of discrete elimination pathways. As free PEG has a longer terminal half-life in plasma than rFVIII, concerns have been raised regarding potential abnormal or even indefinite PEG accumulation with repeated administration of PEGylated coagulation factors in plasma and tissues.

Data presented here show that plasma PEG levels reach steady state in both rats and humans over an extended dosing period and do not increase further. Steady-state plasma PEG levels were predicted to have been reached within the first 1.5 months in rats and within 6 months in humans. In rats, plasma PEG levels decreased markedly within 2 weeks following N8-GP treatment cessation, suggesting that PEG is removed relatively rapidly from plasma once treatment ceases. The rate of decline was in line with the plasma half-life of PEG observed in the single-dose rat study \[[@CR10]\]. As expected, human plasma PEG levels were several fold lower (five- to eightfold) than those reported at the no-observed-adverse-effect-level in the rat toxicity study \[[@CR17]\]. PEG exposure in children was slightly higher than in adults and adolescents, which is likely due to the higher N8-GP (and therefore PEG) dose combined with a shorter dose interval (60 IU/kg twice weekly in the paediatric trial vs. 50 IU/kg Q4D in the adult/adolescent trial).

The semi-mechanistic plasma-tissue pharmacokinetic model based on single-dose distribution data from rats was successful in predicting multiple-dose plasma exposures in rats and humans. The alignment of the measured plasma PEG levels with the model prediction indicates that PEG kinetics are predictable, they adhere to basic pharmacokinetic principles, and are scalable between rats and humans. As only single samples were available from patients receiving N8-GP, full PEG concentration profiles for individual patients could not be analysed. Based on this predictability for rat and human plasma (concentration levels and time to steady state), it seems plausible that rat tissue kinetics would also be predictive for human tissue. This is important as it is not feasible to measure PEG in human tissues.

Data described here for N8-GP also align with those from a recent study examining PEG exposure in patients treated long term with N9-GP, a 40-kDa PEGylated recombinant Factor IX product \[nonacog beta pegol; Refixia^®^ (Novo Nordisk A/S)\] \[[@CR19]\]. This study, which included more samples from each patient, showed that steady-state plasma PEG levels were reached approximately 6 months after initiation of treatment with N9-GP. Plasma PEG levels remained at steady-state concentrations, with trough concentrations of around 5.5 µg/mL in paediatric, adolescent and adult patients over the observed treatment period lasting up to 6.5 years and did not accumulate further. No safety issues were reported that were attributable to PEG, and the safety profile was similar to those of other Factor IX products \[[@CR20], [@CR21]\].

In addition to N8-GP, two other PEGylated FVIII products indicated for the treatment of haemophilia A are currently on the market: BAX 855 \[rurioctocog alfa pegol; Adynovate^®^/Adynovi^®^; 20-kDa PEG (Takeda, Tokyo, Japan)\] and BAY 94 9027 \[damoctocog alfa pegol; Jivi^®^; 60-kDa PEG (Bayer, Leverkusen, Germany)\] (Table [2](#Tab2){ref-type="table"}). PEG exposure from a PEGylated rFVIII is expected to be generally low because of the high potency (IU per mg) and low plasma concentration of FVIII (1 IU/mL equals 100--200 ng/mL in healthy humans \[[@CR22]\]). However, limited PEG exposure data are currently available in the literature. The size of the PEG moiety differs between molecules (20--60 kDa), but the weekly PEG load is comparable. Both predicted and measured plasma PEG concentrations were recently described for BAY 94 9027 \[[@CR23], [@CR24]\]. Simulations using pharmacokinetic data from a rat tissue distribution study predicted a steady-state plasma PEG concentration of 100 ng/mL in humans. Of 179 patients treated with BAY 94 9027 for 0.8--5.4 years, five had detectable plasma PEG concentrations above the LLoQ (100 ng/mL), and the maximum detectable PEG measurement was 119 ng/mL. The applied simulation approach was therefore said to reasonably predict plasma PEG levels in patients treated with BAY 94 9027. By comparison, the mean measured PEG level for all N8-GP-treated patients was 13.3 ng/mL, and the highest measured value was 35.9 ng/mL (Table [2](#Tab2){ref-type="table"}). Clearance is known to decrease with larger PEG molecules, which could explain the differences in steady-state concentrations between the molecules \[[@CR25]\]. No human PEG plasma exposure data have been reported for BAX 855, which has a shorter PEG moiety (20 kDa) but approximately two- to fourfold higher weekly PEG load than N8-GP (clinical PEG dose per week of 7.6--9.5 µg/kg for BAX 855).Table 2PEG dose and exposure from approved PEGylated FVIII molecules indicated for prophylactic treatment of haemophilia AProductEU approvalPEG size, kDaTypical dose described in labelClinical PEG dose per week, µg/kgClinical PEG steady-state plasma concentration, ng/mLBAY 94 902720186060 IU/kg every 5th day or twice weekly \[[@CR11]\] (84--120 IU/kg/week)2.8--4.0\< 100^a^N8-GP20194050--60 IU/kg Q4D or twice weekly \[[@CR29]\] (100--120 IU/kg/week)2.5--3.013.3^b^BAX 85520182040--50 IU/kg twice weekly \[[@CR30]\] (80--100 IU/kg/week)7.6--9.5NA*FVIII* factor VIII, *N8-GP* turoctocog alfa pegol, *NA* not available, *PEG* polyethylene glycol, *Q4D* every 4th day^a^179 patient plasma samples analysed; borderline positive results during the extension were observed in five patients (maximum level: 119 ng/mL) \[[@CR23], [@CR24]\]^b^Calculated combined mean PEG exposure from children, adolescents and adults from this study

While some concerns have been raised regarding the potential for PEG levels to continue to rise during repeated use of PEGylated products \[[@CR26]\], none of the studies examining currently approved PEGylated coagulation factors have reported unexpected PEG accumulation or specific PEG-related safety issues. A recent publication reported significant adverse microscopic alterations to tissue architecture in monkeys administered a 12-kDa protein PEGylated with a 40-kDa PEG moiety. The adverse cell morphology was only seen in the highest dose group with a very high PEG dose of 160 mg/kg/week administered for 3 months, and not in groups receiving 120 mg/kg/week PEG or lower \[[@CR10]\]. The human equivalent dose of PEG \[[@CR27]\] corresponding to the highest dosing group is 51 mg/kg/week, which is around 13,000 times higher than the maximum clinical PEG dose achieved with regular N8-GP use (\~ 4 µg/kg/week). Thus, the PEG dose that contributed to the observed adverse effects on tissue architecture in monkeys is much higher than that achieved with a clinically relevant dose of N8-GP.

Novo Nordisk has assessed all available safety data from 270 patients, including 68 children and 202 adolescents and adults, with up to 5 years of regular prophylactic N8-GP exposure. While the ability for PEG to reach steady state in plasma does not exclude the possibility of longer-term (lifetime) safety concerns, no unexpected safety concerns have been identified so far, and there have been no indications of neurological, renal or hepatic adverse reactions. The safety profile observed for N8-GP was similar to that reported for other (non-PEGylated) FVIII products, including the nature and frequency of the adverse events reported, and no adverse events could be attributed to the presence of PEG \[[@CR28]\].

Conclusion {#Sec11}
==========

Steady-state plasma PEG levels were shown to have been reached in rats and humans receiving regular doses of N8-GP for periods of up to 5 years. Once steady state was reached, no further increase in PEG levels was observed. Plasma steady-state concentrations of PEG in humans were well aligned with values predicted based on rat distribution data. This suggests that modelling based on rat data can be used to predict plasma and tissue concentrations in humans.
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